We found that whilst most studies employing basic testing paradigms show that modafinil intake enhances executive function , only half show improvements in attention and learning and memory , and a few even report impairments in divergent creative thinking .
In contrast , when more complex assessment s are used , modafinil appears to consistently engender enhancement of attention , executive functions , and learning .
Importantly , we did not observe any preponderances for side effects or mood changes .
Modafinil is an FDA -approved eugeroic that directly increases cortical catecholamine levels , indirectly upregulates cerebral serotonin , glutamate , orexin , and histamine levels , and indirectly decreases cerebral gamma-amino-butrytic acid levels .
In addition to its approved use treating excessive somnolence , modafinil is thought to be used widely off-prescription for cognitive enhancement .
However , despite this popularity , there has been little consensus on the extent and nature of the cognitive effects of modafinil in healthy , non-sleep-deprived humans .
Modafinil affects mood, but not cognitive function, in healthy young volunteers.
Modafinil is a selective wakefulness-promoting agent with beneficial effects in narcolepsy and conditions of sleep deprivation . In a double-blind study we examined its effects in 30 healthy , non sleep-deprived students ( 19 men and 11 women , aged 19 - 23 years ) , who were r and omly allocated to placebo , 100 or 200 mg modafinil and 3 h later completed 100 mm visual analogue scales relating to mood and bodily symptoms , before and after an extensive battery of cognitive tests ( pen and paper and CANTAB ) . There were no significant differences between the three treatment groups on any of the cognitive tests used in this study . There was a significant post-treatment change in the factor measuring ' somatic anxiety ' and in individual ratings of ' shaking ' , ' palpitations ' , ' dizziness ' , ' restlessness ' , ' muscular tension ' , ' physical tiredness ' and ' irritability ' , which was mainly due to significantly higher ratings of somatic anxiety in the 100 mg group compared with the other two groups . Further changes in mood were revealed after the stress of cognitive testing , with the 100 mg group showing greater increases in the ' psychological anxiety ' and the ' aggressive mood ' factors ( as measured from the Bond and Lader scales )
We found that whilst most studies employing basic testing paradigms show that modafinil intake enhances executive function , only half show improvements in attention and learning and memory , and a few even report impairments in divergent creative thinking .
In contrast , when more complex assessment s are used , modafinil appears to consistently engender enhancement of attention , executive functions , and learning .
Importantly , we did not observe any preponderances for side effects or mood changes .
Modafinil is an FDA -approved eugeroic that directly increases cortical catecholamine levels , indirectly upregulates cerebral serotonin , glutamate , orexin , and histamine levels , and indirectly decreases cerebral gamma-amino-butrytic acid levels .
In addition to its approved use treating excessive somnolence , modafinil is thought to be used widely off-prescription for cognitive enhancement .
However , despite this popularity , there has been little consensus on the extent and nature of the cognitive effects of modafinil in healthy , non-sleep-deprived humans .